An ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis
Jun‐ichi Abe(The University of Texas MD Anderson Cancer Center), Sivareddy Kotla(University of Tennessee Health Science Center), Keri Schadler(The University of Texas MD Anderson Cancer Center), Jared K. Burks(The University of Texas MD Anderson Cancer Center), Young Jin Gi(The University of Texas MD Anderson Cancer Center), Anisha A. Gupte(Cornell University), Rei Abe(Houston Methodist), Ying H. Shen(Baylor College of Medicine), Cielito C. Reyes‐Gibby(The University of Texas MD Anderson Cancer Center), Sunil Krishnan(Smith Family), Anita Deswal(The University of Texas MD Anderson Cancer Center), Nicolas L. Palaskas(The University of Texas MD Anderson Cancer Center), Elizabeth A. Olmsted‐Davis(William & Mary), John P. Cooke(Houston Methodist), Nhat-Tu Le(Houston Methodist), Eduardo N. Chini(Mayo Clinic in Arizona), Thi-Hong-Minh Nguyen(Houston Methodist), Dale J. Hamilton(Cornell University), Venkata Subrahman K Samanthapudi(The University of Texas MD Anderson Cancer Center), Masaki Imanishi(Tokushima University Hospital), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Robert Dantzer(The University of Texas MD Anderson Cancer Center), Sai‐Ching J. Yeung(The University of Texas MD Anderson Cancer Center), Henry J. Pownall(Cornell University), Angelica Paniagua Bojorges(The University of Texas MD Anderson Cancer Center), Guangyu Wang(Tongji University), Shengyu Li(Jilin Academy of Agricultural Sciences), Joerg Herrmann(Mayo Clinic), Kyung Ae Ko(The University of Texas MD Anderson Cancer Center), Keigi Fujiwara(Norwegian Womens Public Health Association), Aijun Zhang(Cornell University), Momoko Yoshimoto(Brown Foundation), Ling-Ling Lee(The University of Texas MD Anderson Cancer Center), Brian P. Hobbs(Tellabs (Canada))
Cited by 39
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
|The Lancet Diabetes & Endocrinology|2016|728
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589